Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 19;6:66. doi: 10.1038/s41698-022-00301-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Non-supervised clustering of infiltrating immune microenviornment among PL and DLNs through ImmuCellAI. Pie chart indicates the proportion of samples which are antipated as responsive to immunotherapy. R Responder, NR Non-responder. b Comparison of specific immune cell subtypes among different patients. Kruskal-Wallis test was used to testify the difference among patients. Centre dots represent the median value of specific immune cell infiltration. Error bars represent the upper and lower quartiles and whiskers defines the range within 1.5IQR. c Radiological evaluation before and after neoadjuvant immunotherapy for PT4. d Genomic evolutionary trajectory between PL and DLNs of PT4. e Indel- and SNV-induced neoantigens burden among PL and DLNs through NeoPredPipe.